Table 1. Mean utilities of base states and utility decrements associated with treatment toxicities.
| Health state | All mean (s.e.) | Australia mean (s.e.) | UK mean (s.e.) |
|---|---|---|---|
| Clinical response states | |||
| Partial response | 0.88 (0.01) | 0.91 (0.01) | 0.85 (0.02) |
| Stable disease | 0.80 (0.01) | 0.83 (0.01) | 0.77 (0.02) |
| Progressive disease | 0.52 (0.02) | 0.47 (0.03) | 0.59 (0.02) |
| Best supportive care | 0.52 (0.02) | 0.46 (0.03) | 0.59 (0.02) |
| Utility decrement for toxicity states | |||
| Hair loss (grade I/II) | −0.03 (0.01) | −0.03 (0.01) | −0.03 (0.01) |
| Skin reaction (grade I/II) | −0.06 (0.01) | −0.08 (0.01) | −0.03 (0.01) |
| Diarrhoea (grade I/II) | −0.09 (0.01) | −0.11 (0.01) | −0.06 (0.01) |
| Nausea/vomiting (grade I/II) | −0.10 (0.01) | −0.12 (0.01) | −0.07 (0.01) |
| Flu-like syndrome (grade I/II) | −0.11 (0.01) | −0.13 (0.01) | −0.09 (0.01) |
| Stomatitis (grade I/II) | −0.13 (0.01) | −0.14 (0.01) | −0.10 (0.02) |
| 1-day in-/outpatient stay for severe toxicity (grade III/IV) | −0.13 (0.01) | −0.14 (0.01) | −0.11 (0.02) |
| Symptomatic melanomaa | −0.16 (0.01) | −0.20 (0.02) | −0.11 (0.02) |
| 2–5-day hospitalisation for severe toxicity (grade III/IV) | −0.17 (0.01) | −0.20 (0.02) | −0.13 (0.02) |
a
Not a treatment-related toxicity; describes symptoms associated with progressive melanoma.